These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. D1 and D2 and D3. Healy D Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592 [No Abstract] [Full Text] [Related]
7. An un-dopamine hypothesis of schizophrenia. Alpert M; Friedhoff AJ Schizophr Bull; 1980; 6(3):387-9. PubMed ID: 6105705 [TBL] [Abstract][Full Text] [Related]
8. Psychotogenic drugs as models for schizophrenia. Snyder SH Neuropsychopharmacology; 1988 Sep; 1(3):197-9. PubMed ID: 2908018 [No Abstract] [Full Text] [Related]
9. [Dopaminergic receptor activity and the evolution of schizophrenia]. Fodoreanu L Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729 [No Abstract] [Full Text] [Related]
10. Schizophrenia: D4 receptor elevation. What does it mean? Seeman MV J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338 [No Abstract] [Full Text] [Related]
11. Dopamine neuronal tracts in schizophrenia: their pharmacology and in vivo glucose metabolism. Tamminga CA; Burrows GH; Chase TN; Alphs LD; Thaker GK Ann N Y Acad Sci; 1988; 537():443-50. PubMed ID: 2904785 [No Abstract] [Full Text] [Related]
12. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
13. Phenomenological modelling of some mechanisms in schizophrenia. Schwegler H Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S43-9. PubMed ID: 16508895 [TBL] [Abstract][Full Text] [Related]
14. [The dopamine hypothesis of schizophrenia. New findings for an old theory]. Heinz A Nervenarzt; 2000 Jan; 71(1):54-7. PubMed ID: 10695033 [TBL] [Abstract][Full Text] [Related]
15. [The involvement of D-1 and D-2 dopamine receptors in the effects of neuroleptics and the pathogenesis of schizophrenia]. Wielgosz M Psychiatr Pol; 1992; 26(5):357-64. PubMed ID: 1363827 [TBL] [Abstract][Full Text] [Related]
16. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN; Goldsmith SG; Gurevich EV J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Reynolds GP Acta Psychiatr Scand Suppl; 1994; 380():36-40. PubMed ID: 7914046 [TBL] [Abstract][Full Text] [Related]
18. The dopamine hypothesis of schizophrenia revisited. van Kammen DP Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306 [No Abstract] [Full Text] [Related]
19. [Psychopharmacologic approaches to schizophrenic psychoses]. Giacardy-Paty M; Soubrouillard C; Blin O Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339 [TBL] [Abstract][Full Text] [Related]
20. [In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Tadori Y; Kobayashi H Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):265-71. PubMed ID: 25492361 [No Abstract] [Full Text] [Related] [Next] [New Search]